Muscular weakness;Muskelschwäche

Praxis

Volumn 92, Issue 6, 2003, Pages 236-240

  Coppola, G ^a   Butzberger St ^a   Greminger, P ^a   Schulthess, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Grave's disease; Hyperthyroidism; Hypopotassemia; Hypopotassemic periodic paralysis; Tetraparesis

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; POTASSIUM; WARFARIN;

ADULT; ARTICLE; BLOOD; CARDIOVERSION; CASE REPORT; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; MALE; MUSCLE WEAKNESS; TIME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; DIAGNOSIS, DIFFERENTIAL; ELECTRIC COUNTERSHOCK; GRAVES DISEASE; HUMANS; HYPOKALEMIA; MALE; MUSCLE WEAKNESS; POTASSIUM; TIME FACTORS; WARFARIN;

EID: 0037518059     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.92.6.236     Document Type: Article

References (3)

1. Ober KP. Thyreotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992; 71: 109.
2. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokaliemic periodic paralysis. Cell 1994; 77: 863.
3. Sillen A, Sorensen T, Kantola I, et al. Identification of mutations in the CACNL 1A3 gene in 13 families of Scandinavien origin having hypokaliemic periodic paralysis and evidence of a founder effect in Danish families. Am J Med Genet 1997; 69: 102.